Virtual Library
Start Your Search
Miriam Méndez
Author of
-
+
EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Treatment in the Real World - Support, Survivorship, Systems Research
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.16-28 - ALK Translocated Patients: Survival in an Unselected Population (ID 1426)
08:00 - 18:00 | Author(s): Miriam Méndez
- Abstract
Background
Lung cancer is the leading cause of death from cancer in our environment. About 5% have ALK translocation, which is more frequent in young, Asian women and non-smoking patients. In the last years, multiple treatments have been developed for patients with ALK translocation, improving prognosis and reaching overall survivals (OS) of more than two years.
Method
A cohort of 34 patients diagnosed of non-small cell lung cancer with ALK translocation were retrospectively analyzed in our center between 2008-2018. Baseline demographics characteristics were described. OS was calculated as the main objective.
Result
Patients were followed a median of 47 months (IQR 30-203). Median age was 59 years (IQR 36-83), being 47% male and 53% female. 44% were never smokers and 58% had any comorbidities. At diagnosis, 83% were symptomatic and the most frequent metastases were bone ones (32%).
Complete baseline characteristics are shown in Table 1.
Median OS was 32 months (IQR 15-78). 1-year, 2-year and 3- year survival was 75%, 69% 49.9% respectively. Kaplan-Meier curve is shown in Figure 1.
Conclusion
The ALK translocation and targeted treatments have led to a dramatic improvement in overall survival in clinical trials confirmed in our series.